[{"id":"09a2d6c3-0189-486e-8048-e063641e4790","acronym":"","url":"https://clinicaltrials.gov/study/NCT07480694","created_at":"2026-03-28T01:39:28.152Z","updated_at":"2026-03-28T01:39:28.152Z","phase":"","brief_title":"Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With ADC","source_id_and_acronym":"NCT07480694","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 03/01/2026","start_date":" 03/01/2026","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2026-03-18"},{"id":"9563a22f-1431-499b-ba51-cc38d3b74ea7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04345913","created_at":"2021-01-18T21:01:42.609Z","updated_at":"2025-02-25T13:40:07.851Z","phase":"Phase 1/2","brief_title":"Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT04345913","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PIK3CA • PGR • PTEN","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • PIK3CA mutation","tags":["ER • PIK3CA • PGR • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 03/01/2021","start_date":" 03/01/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-21"},{"id":"e34a5a55-d8a1-4469-8532-07c6096c4f21","acronym":"KELLY","url":"https://clinicaltrials.gov/study/NCT03222856","created_at":"2021-01-18T15:54:23.632Z","updated_at":"2025-02-25T14:01:19.405Z","phase":"Phase 2","brief_title":"Ph II Study of Pembrolizumab \u0026 Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines \u0026 Taxanes","source_id_and_acronym":"NCT03222856 - KELLY","lead_sponsor":"MedSIR","biomarkers":" HER-2 • PD-L1 • ER • PGR • TMB","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Halaven (eribulin mesylate)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 12/14/2017","start_date":" 12/14/2017","primary_txt":" Primary completion: 10/31/2018","primary_completion_date":" 10/31/2018","study_txt":" Completion: 12/23/2020","study_completion_date":" 12/23/2020","last_update_posted":"2025-02-19"},{"id":"743006a6-c939-4023-8010-4e3aee085ae3","acronym":"E7386-J081-102","url":"https://clinicaltrials.gov/study/NCT04008797","created_at":"2022-06-28T02:54:50.954Z","updated_at":"2025-02-25T15:18:13.404Z","phase":"Phase 1/2","brief_title":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","source_id_and_acronym":"NCT04008797 - E7386-J081-102","lead_sponsor":"Eisai Inc.","biomarkers":" EGFR • KRAS • BRAF • MSI","pipe":" | ","alterations":" BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • NRAS wild-type","tags":["EGFR • KRAS • BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Lenvima (lenvatinib) • doxorubicin hydrochloride • E7386"],"overall_status":"Recruiting","enrollment":" Enrollment 301","initiation":"Initiation: 07/11/2019","start_date":" 07/11/2019","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2025-02-11"},{"id":"2aaa57e7-ec75-44f1-85ec-6f02f055294b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06590558","created_at":"2025-02-25T16:41:20.201Z","updated_at":"2025-02-25T16:41:20.201Z","phase":"Phase 1","brief_title":"Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer","source_id_and_acronym":"NCT06590558","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RIPK1","pipe":"","alterations":" ","tags":["RIPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • tolinapant (ASTX660)"],"overall_status":"Suspended","enrollment":" Enrollment 42","initiation":"Initiation: 08/04/2025","start_date":" 08/04/2025","primary_txt":" Primary completion: 05/17/2027","primary_completion_date":" 05/17/2027","study_txt":" Completion: 05/17/2027","study_completion_date":" 05/17/2027","last_update_posted":"2025-02-06"},{"id":"63838d90-f82c-44d3-afff-603ca5347be5","acronym":"EPOCH","url":"https://clinicaltrials.gov/study/NCT05619913","created_at":"2023-11-28T05:15:42.216Z","updated_at":"2025-02-25T13:36:18.599Z","phase":"Phase 2","brief_title":"EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma","source_id_and_acronym":"NCT05619913 - EPOCH","lead_sponsor":"Australia New Zealand Gynaecological Oncology Group","biomarkers":" HMGA2","pipe":" | ","alterations":" HMGA2 expression","tags":["HMGA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HMGA2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Halaven (eribulin mesylate)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/22/2023","start_date":" 05/22/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-04"},{"id":"6983d949-ecb2-40d9-9de6-9dd357d15cfa","acronym":"KEYNOTE-C83","url":"https://clinicaltrials.gov/study/NCT05091346","created_at":"2021-10-25T11:52:57.520Z","updated_at":"2025-02-25T16:16:50.707Z","phase":"Phase 1/2","brief_title":"A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors","source_id_and_acronym":"NCT05091346 - KEYNOTE-C83","lead_sponsor":"Eisai Inc.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • E7386"],"overall_status":"Completed","enrollment":" Enrollment 89","initiation":"Initiation: 10/27/2021","start_date":" 10/27/2021","primary_txt":" Primary completion: 10/15/2024","primary_completion_date":" 10/15/2024","study_txt":" Completion: 10/15/2024","study_completion_date":" 10/15/2024","last_update_posted":"2024-10-24"},{"id":"1f6d130c-d54f-44a7-bb36-f1f10bd11cce","acronym":"","url":"https://clinicaltrials.gov/study/NCT02623972","created_at":"2021-01-18T12:45:04.793Z","updated_at":"2025-02-25T13:34:38.183Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer","source_id_and_acronym":"NCT02623972","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Halaven (eribulin mesylate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 02/26/2016","start_date":" 02/26/2016","primary_txt":" Primary completion: 05/01/2021","primary_completion_date":" 05/01/2021","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-09-19"},{"id":"a47ddf13-3816-49fc-80b2-c615e6b61c98","acronym":"","url":"https://clinicaltrials.gov/study/NCT03264664","created_at":"2023-11-04T04:12:31.080Z","updated_at":"2024-07-02T16:34:27.421Z","phase":"Phase 1","brief_title":"Study of E7386 in Participants With Selected Advanced Neoplasms","source_id_and_acronym":"NCT03264664","lead_sponsor":"Eisai Inc.","biomarkers":" CTNNB1","pipe":" | ","alterations":" CTNNB1 mutation","tags":["CTNNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e E7386"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/27/2017","start_date":" 07/27/2017","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-06-11"},{"id":"6230ef3b-69cf-45e4-9b66-1a66fc59f463","acronym":"","url":"https://clinicaltrials.gov/study/NCT05041101","created_at":"2021-09-10T16:57:30.103Z","updated_at":"2024-07-02T16:34:36.959Z","phase":"Phase 1/2","brief_title":"Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer","source_id_and_acronym":"NCT05041101","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • PGR • CD4","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2 • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • grapiprant (RQ-00000007)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 11/04/2021","start_date":" 11/04/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-10"},{"id":"46b13e59-20b7-43c0-af98-d56ecbb4b8e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03237780","created_at":"2021-01-18T15:59:59.860Z","updated_at":"2024-07-02T16:34:58.887Z","phase":"Phase 2","brief_title":"Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer","source_id_and_acronym":"NCT03237780","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • Halaven (eribulin mesylate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 07/20/2018","start_date":" 07/20/2018","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-04"},{"id":"7804b598-a4ee-4247-b0fd-55fd2504d527","acronym":"","url":"https://clinicaltrials.gov/study/NCT02035813","created_at":"2021-01-18T09:20:22.799Z","updated_at":"2024-07-02T16:34:58.978Z","phase":"Phase 2","brief_title":"DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).","source_id_and_acronym":"NCT02035813","lead_sponsor":"Prof. Wolfgang Janni","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HR negative • PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HR negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • Halaven (eribulin mesylate)"],"overall_status":"Completed","enrollment":" Enrollment 116","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 01/10/2024","primary_completion_date":" 01/10/2024","study_txt":" Completion: 01/10/2024","study_completion_date":" 01/10/2024","last_update_posted":"2024-06-04"},{"id":"b6d223e7-2b21-4043-9c4a-6bf6dab3f345","acronym":"SABINA","url":"https://clinicaltrials.gov/study/NCT05810870","created_at":"2023-04-12T14:03:37.667Z","updated_at":"2024-07-02T16:34:59.522Z","phase":"Phase 2","brief_title":"PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin","source_id_and_acronym":"NCT05810870 - SABINA","lead_sponsor":"MedSIR","biomarkers":" PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • izorlisib (MEN1611)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 05/24/2023","start_date":" 05/24/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-06-03"},{"id":"f89835c0-06e4-4e0a-885b-6ba816427d90","acronym":"","url":"https://clinicaltrials.gov/study/NCT03202316","created_at":"2021-01-18T15:47:27.316Z","updated_at":"2024-07-02T16:34:59.898Z","phase":"Phase 2","brief_title":"Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer","source_id_and_acronym":"NCT03202316","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • ER • PGR","pipe":" | ","alterations":" HER-2 positive","tags":["PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cotellic (cobimetinib) • Halaven (eribulin mesylate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/11/2017","start_date":" 08/11/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-31"},{"id":"363c4301-48c3-4930-8568-cf045174c019","acronym":"ARETHA","url":"https://clinicaltrials.gov/study/NCT05570253","created_at":"2022-10-06T13:55:55.168Z","updated_at":"2024-07-02T16:35:00.755Z","phase":"Phase 2","brief_title":"A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer","source_id_and_acronym":"NCT05570253 - ARETHA","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • evexomostat (SDX-7320)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 10/03/2022","start_date":" 10/03/2022","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2024-05-27"},{"id":"bf174275-025d-484c-93f9-5e3ccfbe6e13","acronym":"","url":"https://clinicaltrials.gov/study/NCT01827787","created_at":"2021-01-18T08:07:25.626Z","updated_at":"2024-07-02T16:35:03.572Z","phase":"Phase 2","brief_title":"Eribulin in HER2 Negative Metastatic BrCa","source_id_and_acronym":"NCT01827787","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HR negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate)"],"overall_status":"Completed","enrollment":" Enrollment 83","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 05/01/2016","study_completion_date":" 05/01/2016","last_update_posted":"2024-05-15"},{"id":"df83f8b3-fce6-4513-b771-f6b292dad290","acronym":"","url":"https://clinicaltrials.gov/study/NCT05458674","created_at":"2022-07-14T13:54:27.368Z","updated_at":"2024-07-02T16:35:15.476Z","phase":"Phase 2","brief_title":"Tucatinib+Trastuzumab+Eribulin in HER2+ MBC","source_id_and_acronym":"NCT05458674","lead_sponsor":"Criterium, Inc.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Halaven (eribulin mesylate) • Tukysa (tucatinib) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-03-11"},{"id":"c4f94afc-3a27-4703-8913-5228759041b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03051659","created_at":"2021-01-17T17:47:46.889Z","updated_at":"2025-02-25T16:05:49.933Z","phase":"Phase 2","brief_title":"A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer","source_id_and_acronym":"NCT03051659","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Halaven (eribulin mesylate)"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"Initiation: 03/22/2017","start_date":" 03/22/2017","primary_txt":" Primary completion: 10/11/2018","primary_completion_date":" 10/11/2018","study_txt":" Completion: 09/05/2023","study_completion_date":" 09/05/2023","last_update_posted":"2024-03-06"},{"id":"d1c8d534-b991-4bdd-aee5-250c8074853d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03833700","created_at":"2023-07-12T22:09:04.322Z","updated_at":"2024-07-02T16:35:16.167Z","phase":"Phase 1","brief_title":"A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)","source_id_and_acronym":"NCT03833700","lead_sponsor":"Eisai Co., Ltd.","biomarkers":" RNF43 • APC • AXIN1 • ZNRF3","pipe":" | ","alterations":" APC mutation • CTNNB1 mutation • RNF43 mutation","tags":["RNF43 • APC • AXIN1 • ZNRF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation • CTNNB1 mutation • RNF43 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e E7386"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 03/05/2019","start_date":" 03/05/2019","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-03-06"},{"id":"f12a9fa2-bed6-4d25-ae61-5404aaa84b45","acronym":"BCTOP-T-M01","url":"https://clinicaltrials.gov/study/NCT05806060","created_at":"2023-04-10T14:03:10.896Z","updated_at":"2024-07-02T16:35:20.214Z","phase":"Phase 3","brief_title":"Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT05806060 - BCTOP-T-M01","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • vinorelbine tartrate"],"overall_status":"Recruiting","enrollment":" Enrollment 192","initiation":"Initiation: 04/25/2023","start_date":" 04/25/2023","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2024-02-08"},{"id":"4826d46f-f39c-4ef9-9e0b-32005bc2ffb2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05865002","created_at":"2024-02-01T04:20:40.302Z","updated_at":"2024-07-02T16:35:21.468Z","phase":"Phase 1","brief_title":"A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)","source_id_and_acronym":"NCT05865002","lead_sponsor":"Aurigene Discovery Technologies Limited","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AUR-107"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/05/2023","start_date":" 09/05/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-01-31"},{"id":"f3fa543f-eaf5-4acd-a3d9-1a89668bc625","acronym":"","url":"https://clinicaltrials.gov/study/NCT03568656","created_at":"2021-01-18T17:33:48.014Z","updated_at":"2024-07-02T16:35:22.821Z","phase":"Phase 1/2","brief_title":"Study to Evaluate CCS1477 in Advanced Tumours","source_id_and_acronym":"NCT03568656","lead_sponsor":"CellCentric Ltd.","biomarkers":" MYC • AR • ARID1A • CREBBP","pipe":" | ","alterations":" ARID1A mutation • CREBBP mutation • EP300 mutation","tags":["MYC • AR • ARID1A • CREBBP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation • CREBBP mutation • EP300 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Tecentriq (atezolizumab) • Xtandi (enzalutamide) • abiraterone acetate • Nubeqa (darolutamide) • inobrodib (CCS1477)"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 07/23/2018","start_date":" 07/23/2018","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2024-01-19"},{"id":"ccb78595-92d2-4b8a-8e08-c04b5e5a40e5","acronym":"EMBRACE","url":"https://clinicaltrials.gov/study/NCT02037529","created_at":"2021-01-18T09:21:06.867Z","updated_at":"2024-07-02T16:35:38.039Z","phase":"Phase 3","brief_title":"Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer","source_id_and_acronym":"NCT02037529 - EMBRACE","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" HER-2 • ER • PGR • EPHA5","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR • EPHA5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Halaven (eribulin mesylate)"],"overall_status":"Suspended","enrollment":" Enrollment 201","initiation":"Initiation: 01/17/2014","start_date":" 01/17/2014","primary_txt":" Primary completion: 02/11/2021","primary_completion_date":" 02/11/2021","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-09-06"},{"id":"5cf094cc-3286-4072-a1a8-6e858eb995dd","acronym":"ERI-Based-01","url":"https://clinicaltrials.gov/study/NCT05953909","created_at":"2023-07-20T23:10:47.906Z","updated_at":"2024-07-02T16:35:42.443Z","phase":"","brief_title":"A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01).","source_id_and_acronym":"NCT05953909 - ERI-Based-01","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • docetaxel • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • epirubicin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 08/01/2023","primary_completion_date":" 08/01/2023","study_txt":" Completion: 08/01/2023","study_completion_date":" 08/01/2023","last_update_posted":"2023-07-20"}]